Viltis’ Post

🧬 Gilead Teams Up with Genesis Therapeutics: The Future of Small Molecule Drugs? The biotech world is buzzing as Gilead Sciences announces a partnership with AI startup Genesis Therapeutics. Their goal? To accelerate the discovery of small molecule drugs through the power of AI. This collaboration highlights how artificial intelligence is transforming the drug development process, making it faster and more efficient. At MedMind, we’re excited to see how these innovations will drive new treatments and revolutionize patient care. As AI continues to evolve, what impact do you think it will have on drug discovery and the broader pharmaceutical industry? Share your thoughts! https://lnkd.in/g6FCW2zU #AI #DrugDiscovery #Biotech #MedMind #PharmaceuticalInnovation

Thoughts on this? >> Gilead partners with AI startup Genesis Therapeutics to make small molecule drugs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #healthcare #pharmaceutical #productmarketing

Thoughts on this? >> Gilead partners with AI startup Genesis Therapeutics to make small molecule drugs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #healthcare #pharmaceutical #productmarketing

Could Your Investments Save Lives? Why Not Consider Biopharmaceuticals? 🧪🚀 City Therapeutics, a radiant star in the biopharmaceutical galaxy that specializes in RNA interference-based medicine, has recently announced a monumental raise of $135M in Series A funding. Based out of Cambridge, MA, this revolutionary company is making waves by innovatively and scientifically pushing boundaries. Their latest triumph illustrates their tremendous growth and potential impact on global health. A story worth reading here 👉 https://lnkd.in/gjiU7ZRh It's time to Ignite Corporate Innovation! AI solutions and automation are instrumental tools for corporate growth. Don't miss your chance to join our network of 160K+ corporate decision-makers, investors, and innovative founders dedicated to transforming innovation strategies into successful ventures! Raise the bar for your corporation. Let’s discuss how: https://lnkd.in/gs_bUHEB 💪 #CityTherapeutics #RNAInterference #Biopharma #SeriesAFunding #InvestmentOpportunity #InnovationStrategies #CorporateGrowth #AutomationRevolution #CambridgeMAStartups #GlobalHealthImpact

Could Your Investments Save Lives? Why Not Consider Biopharmaceuticals? 🧪🚀 City Therapeutics, a radiant star in the biopharmaceutical galaxy that specializes in RNA interference-based medicine, has recently announced a monumental raise of $135M in Series A funding. Based out of Cambridge, MA, this revolutionary company is making waves by innovatively and scientifically pushing boundaries. Their latest triumph illustrates their tremendous growth and potential impact on global health. A story worth reading here 👉 https://lnkd.in/gD3GErD6 It's time to Ignite Corporate Innovation! AI solutions and automation are instrumental tools for corporate growth. Don't miss your chance to join our network of 160K+ corporate decision-makers, investors, and innovative founders dedicated to transforming innovation strategies into successful ventures! Raise the bar for your corporation. Let’s discuss how: https://lnkd.in/gH39iDY3 💪 #CityTherapeutics #RNAInterference #Biopharma #SeriesAFunding #InvestmentOpportunity #InnovationStrategies #CorporateGrowth #AutomationRevolution #CambridgeMAStartups #GlobalHealthImpact

🩻🇫🇷 Paris-based AQEMIA, a pioneering #techbio company that combines atomic-scale physics with generative AI to develop innovative medicines, has secured $38 million in additional funding. 📈 The round was led by new investor Cathay Innovation, bringing AQEMIA’s total funding to $100 million. This funding round secured less than a year after their previous one, follows the validation of AQEMIA’s drug discovery platform through results in internal preclinical programs and pharmaceutical partnerships, particularly in oncology. The investment will support AQEMIA’s development goals, including clinical trial preparations and global expansion, beginning with London. 🤖 Read more here: https://lnkd.in/ekYeYGqd Jacky Abitbol Maximilien Levesque #tech #funding #news #EUtech #EUstartup #techstartup #VC #investment #innovation #technology

a concise summary for biotech and biopharma professionals in 2024: 1. Funding Shifts: Larger investments in fewer deals. Companies raised $5.9 billion across 209 deals in Q1 2024. 2. Macrocycles: Start-ups exploring orally available cyclic peptides. Notable players include Insamo and Curve Therapeutics. 3. AI for Drug Discovery: Cloud-based AI tools via subscription (SaaS) now accessible to smaller biotech firms. 4. New Drugs in 2023: FDA approved 55 new drugs, including first-in-class treatments and orphan drug designations. Notable examples: Paxlovid and Leqembi.

If you haven't heard the huge news already, Recursion announced its plan to acquire its smaller peer, Exscientia, for $688 million. This acquisition is part of Recursion's strategy to strengthen its position in the AI-powered drug discovery space. Exscientia, known for its expertise in using AI to design and develop new drugs, will complement Recursion's existing capabilities, potentially accelerating the development of novel therapies. This huge deal highlights the growing importance of AI integration in the pharmaceutical industry, as companies look to leverage technology to speed up drug discovery and reduce costs. #computationalchemistry #drugdiscovery #ai #machinelearning #biotechacquisition

Could Your Investments Save Lives? Why Not Consider Biopharmaceuticals? 🧪🚀 City Therapeutics, a radiant star in the biopharmaceutical galaxy that specializes in RNA interference-based medicine, has recently announced a monumental raise of $135M in Series A funding. Based out of Cambridge, MA, this revolutionary company is making waves by innovatively and scientifically pushing boundaries. Their latest triumph illustrates their tremendous growth and potential impact on global health. A story worth reading here 👉 https://lnkd.in/gD3GErD6 It's time to Ignite Corporate Innovation! AI solutions and automation are instrumental tools for corporate growth. Don't miss your chance to join our network of 160K+ corporate decision-makers, investors, and innovative founders dedicated to transforming innovation strategies into successful ventures! Raise the bar for your corporation. Let’s discuss how: https://lnkd.in/gH39iDY3 💪 #CityTherapeutics #RNAInterference #Biopharma #SeriesAFunding #InvestmentOpportunity #InnovationStrategies #CorporateGrowth #AutomationRevolution #CambridgeMAStartups #GlobalHealthImpact

Could Your Investments Save Lives? Why Not Consider Biopharmaceuticals? 🧪🚀 City Therapeutics, a radiant star in the biopharmaceutical galaxy that specializes in RNA interference-based medicine, has recently announced a monumental raise of $135M in Series A funding. Based out of Cambridge, MA, this revolutionary company is making waves by innovatively and scientifically pushing boundaries. Their latest triumph illustrates their tremendous growth and potential impact on global health. A story worth reading here 👉 https://lnkd.in/gD3GErD6 It's time to Ignite Corporate Innovation! AI solutions and automation are instrumental tools for corporate growth. Don't miss your chance to join our network of 160K+ corporate decision-makers, investors, and innovative founders dedicated to transforming innovation strategies into successful ventures! Raise the bar for your corporation. Let’s discuss how: https://lnkd.in/gH39iDY3 💪 #CityTherapeutics #RNAInterference #Biopharma #SeriesAFunding #InvestmentOpportunity #InnovationStrategies #CorporateGrowth #AutomationRevolution #CambridgeMAStartups #GlobalHealthImpact